2. Anti-infection Neuronal Signaling Apoptosis
  3. SARS-CoV Amyloid-β Ferroptosis Tau Protein Caspase Bcl-2 Family
  4. Verbenalin

Verbenalin is an orally active terpenoid glycoside that can be extracted from the medicinal plant Verbena officinalis. Verbenalin has anti-inflammatory, antiviral, and neuroprotective effects. Verbenalin has a strong binding affinity to the nsp-12 protein of the SARS-CoV-2 virus. Verbenalin can be used in the research of inflammatory and nervous system diseases such as hepatitis and Alzheimer's disease.

For research use only. We do not sell to patients.

Verbenalin Chemical Structure

Verbenalin Chemical Structure

CAS No. : 548-37-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Verbenalin:

Verbenalin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Verbenalin

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Verbenalin is an orally active terpenoid glycoside that can be extracted from the medicinal plant Verbena officinalis. Verbenalin has anti-inflammatory, antiviral, and neuroprotective effects. Verbenalin has a strong binding affinity to the nsp-12 protein of the SARS-CoV-2 virus. Verbenalin can be used in the research of inflammatory and nervous system diseases such as hepatitis and Alzheimer's disease[1][2][3][4][5].

In Vitro

Verbenalin (1-100 μM; 24 h) can downregulate the levels of APP and Aβ42 in APP-overexpressing N2a cells, while there is no significant change in the level of Aβ40[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Verbenalin Related Antibodies

Western Blot Analysis[1]

Cell Line: APP-overexpressing N2a cells
Concentration: 1, 3, 10, 30 and 100 μM
Incubation Time: 24 h
Result: Inhibited the APP protein levels in cell lysate and supernatant.
In Vivo

Verbenalin (100-200 mg/kg; gavage; 35 days) reduces the levels of Aβ and tau in the hippocampus and restores the expression of BDNF in the AD mouse model[1].
Verbenalin (50-200 mg/kg; gavage; 21 days) has an improving effect in the mouse prostatitis model[2].
Verbenalin (5-20 mg/kg; intravenous injection; single dose) has a protective effect in the rat model of focal cerebral ischemia-reperfusion[3].
Verbenalin (12.5-50 mg/kg; gavage; 16 days) can alleviate liver injury, regulate lipid homeostasis, inhibit oxidative stress-induced ferroptosis, and improve mitochondrial function in the mouse model of alcoholic steatohepatitis[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: KM male mice (24-26 g) treated Xiaozhiling to induce prostatitis model[2]
Dosage: 50, 100 and 200 mg/kg
Administration: Oral gavage (i.g.); 21 days
Result: Had significantly increased amounts of water, and prostate white blood cell count and prostate volume density were decreased significantly, the density of lecithin corpuscle score increased, and pathologic prostatitis changes were significantly reduced.
Significantly reduced pathological change in the testis and the change in the epididymis.
Increased significantly the thymic cortex thickness and the number of lymphocytes.
Reduce the renal pathological changes in potential.
Animal Model: Male KM rats (25-30 g) with focal cerebral ischemia reperfusion[3]
Dosage: 5, 10 and 20 mg/kg
Administration: Intravenous injection (i.v.); single dose
Result: Significantly reduced the mortality rate, neurological deficit score and the percentage of cerebral infarction size.
Significantly reduced the levels of Bax, Caspase-3, S-100β level of the serum in the brain tissue.
Increased the levels of Bcl-2 and ATPase in brain tissue and improved pathological damage of hippocampus and cortex.
Inhibited the expression of apoptosis genes, promoted the expression of anti-apoptosis genes, improved brain microcirculation and energy metabolism, hence reducing cerebral ischemia-reperfusion injury.
Molecular Weight

388.37

Formula

C17H24O10
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CO[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)[C@@]3([H])[C@]1([H])C(C[C@@H]3C)=O)OC
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (257.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5749 mL 12.8743 mL 25.7486 mL
5 mM 0.5150 mL 2.5749 mL 5.1497 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 25 mg/mL (64.37 mM); Clear solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 50 mg/mL (128.74 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.91%

SDS (393 KB)

COA (253 KB) RP-HPLC (247 KB) MS (70 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5749 mL 12.8743 mL 25.7486 mL 64.3716 mL
5 mM 0.5150 mL 2.5749 mL 5.1497 mL 12.8743 mL
10 mM 0.2575 mL 1.2874 mL 2.5749 mL 6.4372 mL
15 mM 0.1717 mL 0.8583 mL 1.7166 mL 4.2914 mL
20 mM 0.1287 mL 0.6437 mL 1.2874 mL 3.2186 mL
25 mM 0.1030 mL 0.5150 mL 1.0299 mL 2.5749 mL
30 mM 0.0858 mL 0.4291 mL 0.8583 mL 2.1457 mL
40 mM 0.0644 mL 0.3219 mL 0.6437 mL 1.6093 mL
50 mM 0.0515 mL 0.2575 mL 0.5150 mL 1.2874 mL
60 mM 0.0429 mL 0.2146 mL 0.4291 mL 1.0729 mL
80 mM 0.0322 mL 0.1609 mL 0.3219 mL 0.8046 mL
100 mM 0.0257 mL 0.1287 mL 0.2575 mL 0.6437 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Verbenalin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Verbenalin548-37-8SARS-CoVAmyloid-βFerroptosisTau ProteinCaspaseBcl-2 FamilySARS coronavirusβ-amyloid peptideAβAbetaAD mouse modelprostatitis modelfocal cerebral ischemia-reperfusion model alcoholic steatohepatitis modelN2a cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Verbenalin
Cat. No.:
HY-N2014
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.